Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.

Sterckx, Mira et al.·Cureus·2026·

Quick Facts

Study Type

Not classified

Evidence

Not graded

Sample

Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:: Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.
Published In:: Cureus, 18(1), e102627 (2026)
Authors:: Sterckx, Mira, De Keyser, Ludo
Database ID:: RPEP-16173

Evidence Hierarchy

Meta-Analysis / Systematic Review

Randomized Controlled Trial

Cohort / Case-Control

Cross-Sectional / ObservationalSnapshot without intervening

This study

Case Report / Animal Study

What do these levels mean? →

Cite This Study

RPEP-16173·https://rethinkpeptides.com/research/RPEP-16173

APA

Sterckx, Mira; De Keyser, Ludo. (2026). Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.. Cureus, 18(1), e102627. https://doi.org/10.7759/cureus.102627

MLA

Sterckx, Mira, et al. "Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.." Cureus, 2026. https://doi.org/10.7759/cureus.102627

RethinkPeptides

RethinkPeptides Research Database. "Euglycemic Ketoacidosis Following the Use of Counterfeit Sem..." RPEP-16173. Retrieved from https://rethinkpeptides.com/research/sterckx-2026-euglycemic-ketoacidosis-following-the

Access the Original Study

View on PubMed View via DOI

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.

← Back to Research Database